06/08/11 Portland, Ore.
The Department of Pathology's George Thomas, MD, weighs in on study
OHSU Knight Cancer Institute study uncovers role of gene in renal cancers that don’t respond to current therapies but could be helped by existing FDA-approved drug.
The OHSU study, published in the June 1 edition of Science Translational Medicine, identified a gene called Src that helps certain kidney cancers grow. Discovering that Src plays a role in kidney cancer could help in delivering more effective, individualized treatments to patients, said George Thomas, MD, Associate Professor, Department of Pathology, the study’s senior author and a surgical pathologist at the OHSU Knight Cancer Institute.
The next step, said Dr. Thomas , is initiating clinical trials to test how these tumors respond to drugs already available and approved by the FDA.
- The full OHSU media release is available online